Rangaswamy Govindarajan, M.D. | UAMS Health

Dr. Rangaswamy Govindarajan

Claim this profile

John L McClellan Memorial Veterans Hospital

Studies Lung Cancer
Studies Prostate Cancer
10 reported clinical trials
42 drugs studied

Area of expertise

1

Lung Cancer

Rangaswamy Govindarajan has run 3 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
ALK positive
Stage I
2

Prostate Cancer

Rangaswamy Govindarajan has run 2 trials for Prostate Cancer. Some of their research focus areas include:

Stage IV

Affiliated Hospitals

Image of trial facility.

John L McClellan Memorial Veterans Hospital

Image of trial facility.

University Of Arkansas For Medical Sciences

Clinical Trials Rangaswamy Govindarajan is currently running

Image of trial facility.

Nivolumab + Standard Treatment

for Stomach and Esophageal Cancer

This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.

Recruiting

1 award

Phase 2 & 3

20 criteria

Image of trial facility.

Perioperative Chemotherapy

for Pancreatic Cancer

This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).

Recruiting

4 awards

Phase 3

18 criteria

More about Rangaswamy Govindarajan

Clinical Trial Related

7 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Rangaswamy Govindarajan has experience with

  • Crizotinib
  • Abiraterone Acetate
  • Cabazitaxel
  • Antiandrogen Therapy
  • Prednisone
  • Ulixertinib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Rangaswamy Govindarajan specialize in?

Is Rangaswamy Govindarajan currently recruiting for clinical trials?

Are there any treatments that Rangaswamy Govindarajan has studied deeply?

What is the best way to schedule an appointment with Rangaswamy Govindarajan?

What is the office address of Rangaswamy Govindarajan?

Is there any support for travel costs?